AroCell AB (publ) (AROC.ST)
AroCell AB (publ) operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Uppsala, SE. The stock last traded at $0.57, up 0.00% on the session, giving a market capitalisation of $132.2M. Its beta of 1.21 implies it has historically moved more than the broad market.
AroCell AB (publ) is an in vitro diagnostics enterprise primarily focused on the surveillance of various cancerous conditions, such as hematological malignancies, breast cancer, and other solid tumors. The company develops, produces, and markets its flagship product, AroCell TK 210 ELISA, an immunoassay kit designed for measuring Thymidine Kinase 1 levels in human blood. Additionally, AroCell provides TUBEX TF, a rapid bacteriological test for the detection of typhoid fever. Founded in 2000, the firm was originally known as Xi Bao Research AB, adopting its current name, AroCell AB (publ), in 2006. It maintains its headquarters in Uppsala, Sweden.
AroCell AB (publ) is most often compared with the following Healthcare names: